Prelude Capital Management’s Viking Therapeutics VKTX Stock Holding History

Prelude Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,051	Closed	-$490K	–	1549
2026 Q1	$490K	Buy	+15,051	New	+$484K	0.04%	525
2025 Q2	–	Sell	-52,467	Closed	-$1.27M	–	1383
2025 Q1	$1.27M	Sell	52,467 -1,299	-2%	-$41.1K	0.1%	255
2024 Q4	$2.16M	Buy	+53,766	New	+$3.07M	0.14%	170
2019 Q3	–	Sell	-23,328	Closed	-$194K	–	2072
2019 Q2	$194K	Sell	23,328 -32,578	-58%	-$278K	0.01%	743
2019 Q1	$556K	Buy	55,906 +24,872	+80%	+$208K	0.03%	471
2018 Q4	$237K	Buy	31,034 +29,394	+1,792%	+$351K	0.02%	674
2018 Q3	$29K	Sell	1,640 -77,872	-98%	-$927K	﹤0.01%	1243
2018 Q2	$755K	Buy	+79,512	New	+$529K	0.05%	405

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Prelude Capital Management's VKTX Position: Q2 2026 in Review

Prelude Capital Management sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 15,051 shares — an estimated $490K sold.

Prelude Capital Management first reported a position in VKTX in Q2 2018 and held it in 8 quarters. The position peaked at $2.16M in Q4 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Prelude Capital Management reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 15,051 Viking Therapeutics shares in Q2 2026, an estimated $490K.
Prelude Capital Management first reported a position in Viking Therapeutics in Q2 2018 and held it in 8 quarters.
Prelude Capital Management's Viking Therapeutics position peaked at $2.16M in Q4 2024.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.